Eli Lilly's triple hormone drug retatrutide delivers 16.8% weight loss in phase 3 trial
The next generation of weight loss drugs is already in trials. Lilly's retatrutide delivered nearly 17% weight loss in 40 weeks, with patients still losing weight at the end of the trial.
The next generation of weight loss drugs is already in trials. Lilly's retatrutide delivered nearly 17% weight loss in 40 weeks, with patients still losing weight at the end of the trial.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
